Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231897 | 0.85 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL28947571 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL29184186 | 0.84 | KDR (0.76) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL3099619 | 0.83 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL23963298 | 0.83 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037590 | 0.83 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL10415452 | 0.83 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL20990144 | 0.83 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL18993402 | 0.83 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL7988912 | 0.83 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116870968-B | Iridium complex functionalized nano graphene catalyst, and preparation method and application thereof | 烟台大学 | 2023-11-10 | — | — | CN | claimed |
| CN-116870968-A | Iridium complex functionalized nano graphene catalyst, and preparation method and application thereof | 烟台大学 | 2023-10-13 | — | — | CN | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| CN-112703183-B | Aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-07-25 | — | — | US | disclosed |
| CN-117753408-A | Preparation method of platinum-based catalyst for hydrogen isotope catalytic exchange | 天津大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| CN-116870968-B | Iridium complex functionalized nano graphene catalyst, and preparation method and application thereof | 烟台大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-116870968-B | Iridium complex functionalized nano graphene catalyst, and preparation method and application thereof | 烟台大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2018-11-08 | — | — | US | disclosed |
| WO-2018136634-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-2900238-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | UNIV VANDERBILT (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2853565-A1 | Glutamate receptor photomodulators | Consejo Superior De Investigaciones Científicas (ES) | 2015-04-01 | — | — | EP | disclosed |
| EP-2853565-A1 | Glutamate receptor photomodulators | Consejo Superior De Investigaciones Científicas (ES) | 2015-04-01 | — | — | EP | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | NPC1 2733/4885RAB9A 2884/4885SMN1; SMN2 1866/4885 |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | NPC1 2017/4885RAB9A 1327/4885SMN1; SMN2 713/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | NPC1 1274/4885RAB9A 1238/4885SMN1; SMN2 894/4885 |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, ADRM1, UBQLN2 | NPC1 1072/4885RAB9A 967/4885SMN1; SMN2 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.